Market news
Moby summary of Aytu BioPharma, Inc.'s Q4 2026 earnings call
Aytu BioPharma Inc (AYTU) posted $16.1 million in Q4 FY2026 revenue as EXXUA prescriptions surged 138% and the company swung to positive adjusted EBITDA of $0.5 million.
On Tuesday, Aytu BioPharma (NASDAQ:AYTU) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time
DENVER, CO / ACCESS Newswire / September 16, 2026 / (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 20
Detailed price information for California Resources Corp (CRC-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.